Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

被引：0
|
作者：
Mansilla-Polo, Miguel [1 ,2 ]
Sahuquillo-Torralba, Antonio [1 ,2 ]
Pujol-Marco, Conrad [1 ,2 ]
Bargues-Navarro, Guillermo [1 ,2 ]
Botella-Estrada, Rafael [1 ,2 ,3 ]
机构：
[1] Hosp Univ & Politecn La Fe, Dept Dermatol, Valencia, Spain
[2] Inst Invest Sanitaria La Fe IIS La Fe, Dept Dermatol, Valencia, Spain
[3] Univ Valencia, Fac Med, Dept Dermatol, Valencia, Spain
来源：
ANAIS BRASILEIROS DE DERMATOLOGIA | 2024年 / 99卷 / 06期
关键词：
D O I：
10.1016/j.abd.2024.04.004
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：922 / 927
页数：6
相关论文
共 50 条
  • [31] Data to support a head-to-head comparative study of bladder retraining against an antimuscarinic agent in the treatment of the overactive bladder
    Ghei, M
    Malone-Lee, J
    NEUROUROLOGY AND URODYNAMICS, 2005, 24 (5-6) : 497 - 498
  • [32] Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
    Orsini, Diego
    Assorgi, Chiara
    Bonifati, Claudio
    Cameli, Norma
    Graceffa, Dario
    Potestio, Luca
    Megna, Matteo
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [33] Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
    Yang, Jing
    Hu, Kun
    Li, Xingyu
    Hu, Jingjin
    Tan, Minjia
    Zhang, Mi
    Kuang, Yehong
    Lv, Chengzhi
    Chen, Junchen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 477 - 485
  • [34] Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia
    Yazed AlRuthia
    Almaha H. Alfakhri
    Ibtisam Alharbi
    Fadi Ali Alghamdi
    Miteb A. Alanazi
    Abdullah Abdulrahman Alrabiah
    Anwar Abdulrazzag Alsouan
    Abdulrahman Abdullah Alshaikh
    Majed Ali Almasaoud
    Cost Effectiveness and Resource Allocation, 21
  • [35] Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia
    AlRuthia, Yazed
    Alfakhri, Almaha H.
    Alharbi, Ibtisam
    Alghamdi, Fadi Ali
    Alanazi, Miteb A.
    Alrabiah, Abdullah Abdulrahman
    Alsouan, Anwar Abdulrazzag
    Alshaikh, Abdulrahman Abdullah
    Almasaoud, Majed Ali
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [36] Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
    Jing Yang
    Kun hu
    Xingyu Li
    Jingjin Hu
    Minjia Tan
    Mi Zhang
    Yehong Kuang
    Chengzhi Lv
    Junchen Chen
    Dermatology and Therapy, 2023, 13 : 477 - 485
  • [37] Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [38] In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease
    Meserve, Joseph
    Barsky, Maria
    Dulai, Parambir S.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2019, 38-39
  • [39] Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
    Bagit, Ahmed
    Maliyar, Khalad
    Georgakopoulos, Jorge R.
    Rimke, Alexander
    Rankin, Brian
    Mufti, Asfandyar
    Le, Heather
    Vender, Ronald
    Prajapati, Vimal H.
    Yeung, Jensen
    JAAD INTERNATIONAL, 2023, 12 : 136 - 138
  • [40] Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to-head clinical trials
    Armstrong, April
    Blauvelt, Andrew
    Papp, Kim A.
    Green, Lawrence J.
    Feely, Meghan
    Malatestinic, William N.
    See, Kyoungah
    McKean-Matthews, Missy
    Strober, Bruce E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB12 - AB12
12345